Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

McGill University2 个研究点分布在 1 个国家目标入组 15 人开始时间: 2008年10月最近更新: 2008年10月24日

适应症

试验速览

阶段: 1 期
发起方: McGill University
入组人数: 15
试验地点: 2
主要终点: Partial response (PR) is defined as some improvement (25%-50%);significant evidence of disease remains or disease has not changed from baseline condition (<25%);no new clinically abnormal(>1.5 cm)lymph nodes,<25% progression of existence

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients with Stage I-IIA CTCL must be at least 18 years of age with a skin biopsy prior to enrolment confirming the diagnosis of mycosis fungoides.

排除标准

•Patients with Stage >IIA CTCL at the time of enrolment
•Women who are pregnant or planning to get pregnant, or unable/unwilling to use adequate contraception
•Patients who were treated with topical retinoid therapy in the past 3 months
•Patients who received any systemic CTCL therapy or systemic corticosteroid therapy within 30 days of the study start date
•Patients who were treated with systemic isotretinoin or bexarotene within 3 months prior to the study start date, systemic acitretin within 2 years prior to study start date

结局指标

主要结局

Partial response (PR) is defined as some improvement (25%-50%);significant evidence of disease remains or disease has not changed from baseline condition (<25%);no new clinically abnormal(>1.5 cm)lymph nodes,<25% progression of existence

次要结局

未报告次要终点

研究者

发起方

McGill University

申办方类型

Other

研究点 (2)

Loading locations...

相似试验

已完成

4 期

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle NailsBrittle Nails

NCT00648986Columbia University20

已完成

1 期

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne VulgarisAcne Vulgaris

NCT02411955Taro Pharmaceuticals USA1,077

已完成

3 期

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque PsoriasisPlaque Psoriasis

NCT02160665G & W Laboratories Inc.866

已完成

4 期

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With AcneAcne VulgarisPost Inflammatory HyperpigmentationPost Inflammatory Pigmentation ChangeErythemaSkin Scarring

NCT05704114Dr. Emmy Graber20

终止

4 期

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne VulgarisAcne Vulgaris

NCT00829049Allergan165